WillItSurvive
Pharma and healthcare groups · India

Glenmark Pharmaceuticals

glenmarkpharma.com ↗

Indian generics and specialty pharma pivoting toward innovative biologics via licensing deals.

Defensible for now
Assessed 26 July 2026 · Evidence as of 26 July 2026
Real protection, with named pressure against it.
On the recordSince 26 July 2026 · Checkable from late 2026 or early 2027 · Every call on the record Checkpoint: Hartford antitrust trial (33 generic-drug defendants) expected to begin
The call

A stable generics base funds a bet on novel biologics, with tariffs, price wars, and a pending antitrust trial as the main swing factors.

Glenmark makes and sells generic medicines (copies of brand-name drugs) and operates factories in four countries with government approval to do so. The company is not easy to replace because it has these regulated factories, sells to fifty countries, and owns the right to make certain generic versions before competitors can. However, it faces the same brutal price wars as rivals like Sun Pharmaceutical and Dr. Reddy's, while also betting everything on a single new drug called ISB 2001 that it sold to AbbVie in a deal worth up to $1.9 billion. The one thing that matters most is whether this experimental medicine actually works in human trials and whether it can become a real money-maker before generic price pressure crushes the old business.

Why
01
AI pressure: AI-driven drug discovery labs like Isomorphic Labs and Insilico Medicine. AI-native biotech labs could out-design novel biologics faster than Glenmark's traditional R&D pipeline, though no direct clash yet. Could AI do the core job? Unlikely.
02
Bigger players: Sun Pharmaceutical, Dr. Reddy's Laboratories, Cipla. Rival Indian generics giants compete in the same semaglutide and respiratory ANDA markets, driving price wars that compress margins. Could a giant copy it? Probably.
03
What protects it. Near-debt-free balance sheet, multi-country GMP plants, 50+ country distribution, and fresh AbbVie licensing cash for the innovation pivot.
What would change this call
ISB 2001 Phase 1 trial data readout. Would show whether the AbbVie-partnered innovative pivot has real clinical legs or stalls.
US generic tariff phase-in reaching 15%+ within the 2-year window. Would show direct margin hit to roughly 35% of Glenmark's revenue base.
Hartford antitrust trial outcome (expected late 2026/early 2027). Would show whether legal overhang against Glenmark ends cleanly or adds new payouts.
Key numbers
  • Q3 FY26 revenue ₹3,900 crore, up 15.1% YoY (2026-01-30)
  • AbbVie deal: $700M upfront plus $1.225B milestones (2025-07-09)
  • Q1 FY26 net profit fell 86% YoY to ₹47 crore (2025-08-17)
Named risks
  • Ongoing US antitrust litigation with 33 remaining defendants, trial expected late 2026 or early 2027 in Hartford CT. Severity: high
  • Proposed US tariffs on generic drug imports could hit the ~35% of revenue derived from the US market. Severity: high
  • Semaglutide price war among 50 plus Indian brands could compress margins on the March 2026 Glipiq launch. Severity: medium
  • ISB 2001 remains only in Phase 1 trials; a clinical setback would undercut the AbbVie partnership's future value. Severity: medium
  • Quarter to quarter revenue volatility, Q4 FY26 revenue fell 3.3% sequentially despite 15.8% annual growth. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Sun Pharmaceutical Industrieslosing toDescribed as India's largest pharma company, leads GLP-1 generics race launched March 2026
Dr. Reddy's LaboratoriescontestingDirect rival in 50 plus brand semaglutide price war in India, March 2026 onward
Zydus LifesciencescontestingCo-launched generic semaglutide in India alongside Glenmark, March 2026
AbbViegaining onBecame partner not rival via $700M ISB 2001 licensing deal, July 2025
Cipla, Lupin, Aurobindo, Torrent PharmaceuticalscontestingPeer group with matching ANDA and distribution footprint per November 2025 industry report
Questions people ask
Is Glenmark Pharmaceuticals profitable in 2026?
Yes. Glenmark posted Q3 FY26 (Oct to Dec 2025) net profit of ₹403 crore, up about 16% year over year, on revenue of ₹3,900 crore. Q4 FY26 revenue reached ₹3,770.59 crore, up 15.8% year over year, reported July 24, 2026.
Did Glenmark Pharmaceuticals have a bad quarter recently?
Yes. In Q1 FY26 (April to June 2025), Glenmark's net profit fell about 86% year over year to just ₹47 crore, mainly due to a litigation-related provision tied to a US generic drug price-fixing antitrust case, despite revenue of ₹3,264 crore.
Who is Glenmark Pharmaceuticals' biggest competitor?
Sun Pharmaceutical Industries is the closest Indian incumbent, alongside Dr. Reddy's, Cipla, Lupin, Aurobindo, Zydus and Torrent. In India's semaglutide generics race launched March 2026, Glenmark competes directly against 50 plus branded rivals including Sun Pharma and Dr. Reddy's.
Could AI replace Glenmark Pharmaceuticals?
No. Glenmark's core value sits in ANDAs, FDA approvals, GMP manufacturing across four countries and distribution in 50 plus markets, moats AI cannot replicate. The company uses AI internally to speed small-molecule drug discovery and Phase III data analysis, per February 2026 reports, not as a replacement threat.
Is Glenmark Pharmaceuticals involved in any lawsuits?
Yes. In July 2026, Glenmark settled with 48 US state attorneys general for $29.6 million over a generic-drug price-fixing conspiracy spanning 2009 to 2019. It must still cooperate in litigation against 33 remaining defendants, with a first trial expected in Hartford, CT in late 2026 or early 2027.
What is Glenmark's biggest new revenue opportunity?
Its Ichnos Glenmark Innovation unit licensed oncology candidate ISB 2001, a trispecific antibody for multiple myeloma, to AbbVie in July 2025 for $700 million upfront plus up to $1.225 billion in milestones and tiered double-digit royalties, marking its pivot toward innovative biologics.
Timeline
  • 2026-07-24Q4 FY26 revenue reported at ₹3,770.59 crore, down 3.3% quarter over quarter, up 15.8% year over year
  • 2026-07-21Chairman Glenn Saldanha says innovative products could drive about 70% of revenue within 5 to 6 years
  • 2026-07-15Glenmark settles with 48 US state AGs for $29.6 million over generic-drug price-fixing conspiracy
  • 2026-03-21Glenmark launches generic semaglutide Glipiq in India priced ₹325 to 440 per week
  • 2026-01-30Q3 FY26 revenue ₹3,900 crore, up 15.1% year over year, net profit up 16% to ₹403 crore
  • 2025-08-17Q1 FY26 net profit falls 86% year over year to ₹47 crore on litigation provision
  • 2025-07-09Ichnos Glenmark Innovation licenses ISB 2001 to AbbVie for $700 million upfront plus milestones
  • 2024-07-10Glenmark exits residual 7.84% stake in Glenmark Life Sciences via OFS
  • 2024-01Formation of Ichnos Glenmark Innovation combining oncology R&D with Ichnos Sciences
  • 2023-09-21Glenmark agrees to sell 75% of Glenmark Life Sciences to Nirma for about ₹5,651.5 crore
Revision history
26 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
ZoetisBoston ScientificBecton Dickinson
More in Pharma and healthcare groups →
Sources